WAVE Life Sciences (STU:1U5) ROCE % : 43.91% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. WAVE Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2024 was 43.91%.

WAVE Life Sciences ROCE % Historical Data

The historical data trend for WAVE Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences ROCE % Chart

WAVE Life Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-90.21

-87.68

-155.90

-82.13

-67.68

WAVE Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-78.40	-174.89	-268.14	-227.68	43.91

WAVE Life Sciences ROCE % Calculation

WAVE Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-105.435	/	( ( (252.128 - 170.965)	+	(336.358 - 105.96) )	/ 2 )
	=	-105.435	/	( (81.163	+	230.398)	/ 2 )
	=	-105.435	/	155.7805
	=	-67.68 %

WAVE Life Sciences's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	87.732	/	( ( (323.012 - 153.826)	+	(336.358 - 105.96) )	/ 2 )
	=	87.732	/	( ( 169.186	+	230.398 )	/ 2 )
	=	87.732	/	199.792
	=	43.91 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

WAVE Life Sciences (STU:1U5) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

WAVE Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

WVE:USA 1U5:Germany

Address

7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines